The latest data reported by the National Health Commission on October 24 shows that there are 3,784 confirmed cases of new coronary pneumonia (including 15 severe cases).
Previously, the social areas were cleared and sporadic cases also occurred. For example, infected people found by social screening have appeared in Beijing for several consecutive days, and clustered epidemics still have hidden dangers.
The number of people vaccinated against the new crown vaccine in my country has exceeded 1.3 billion, and the vaccination rate has reached more than 90%. Many netizens believe that it is time to let go based on the current vaccination rate. Is this view correct? Can the vaccination rate of new crown vaccine end the epidemic? Science and Technology Daily reporter interviewed relevant experts.
data picture. Xinhua News Agency reporter Ju Huanzong photographed
Reporter: The current vaccination rate has reached more than 90%, has the immune barrier not been established yet?
Chinese Academy of Sciences Academician Gao Fu : The immune barrier established by the vaccine provides level 4 protection, prevent infection, prevent disease, transmission, severe illness and death. Big data from the world shows that the prevention of severe illness and death is very effective, and the immune barrier of first-level protection has been basically established.
However, due to the mutant characteristics of the virus, the immune barriers in preventing infection, disease and transmission still need to be strengthened.
Zhu Tao, chief scientific officer of CanSino Biologics: Multiple international and domestic studies have shown that no matter which technical route of COVID-19 vaccine is vaccinated, the neutralizing antibodies in the body will increase quickly, but the attenuation will also be faster. For example, clinical data of mRNA vaccines abroad show that after 6 months of the third dose, the level of neutralizing antibodies in the human body becomes lower. Therefore, some countries have continuously given enhanced injections to block the spread of the epidemic. For example, , Israel, and other countries have carried out the fourth and fifth doses of the original vaccine, but this is not a long-term solution.
Reporter: What is the key to blocking the epidemic?
Academician Gao Fu of the Chinese Academy of Sciences: Blocking the epidemic requires an immune barrier. After the immune barrier is established, a breakthrough infection occurs. The game between humans and viruses is like a "cat and mouse game", always competing. is currently calling on everyone not to have "vaccine hesitation" and should be vaccinated with enhanced injections as soon as possible, and whether the fourth injection will be given in will be given in the subsequent period and what kind of fourth injection will be given. The country will compare it to further analyze and judge based on the epidemic situation and risk benefits. Zhu Tao, chief scientific officer of CanSino Biologics : In order to block the epidemic, the role of the vaccine should not only reduce the incidence rate, but also fully reduce the infection rate in order to truly control the epidemic.
If the epidemic cannot be blocked, the infection and transmission of the new coronavirus will always exist in the population, which means it has the opportunity to continue to mutation, produce new mutant strains, and form a cycle of infection-mutation-epidemic development-reinfection.
Reporter: Immunity still needs to be strengthened again. What effect should be achieved?
Lizon Mab Research Head Hu Zhenxiang: Strengthening it further cannot be based on the original vaccine, but a new vaccine strategy. Sequential enhancement of vaccines with different technical routes in is very critical, and can induce higher neutralizing antibodies than homologous enhancement. is currently the only Likang V01 vaccine research in China that has completed the large-scale Phase III clinical study of the Omickron variant strain. It shows that by arming the vaccine with "three heads and six arms", it stimulates auxiliary antibodies and T cell responses, and its absolute protection rate against the new coronavirus (including Omickron mutant strain) can reach 61.35%. Currently, vaccination is available in Anhui, Guangdong and other places.
Zhu Tao, chief scientific officer of CanSino Biologics: stimulating mucosal immunity is recommended for use by World Health Organization , which can achieve twice the result with half the effort. It creates IgA and cellular immunity on the surface of the body's mucosa, and captures and removes the new coronavirus as soon as it enters, which has more positive significance for blocking transmission.
CanSino inhalation vaccine is the world's first approved inhalation coronavirus vaccine. It is currently undergoing vaccination training and preparation. There are currently more than a dozen clinical products of nasal spray and inhalation vaccines in countries around the world, and it is becoming a consensus to stimulate mucosal immunity to block the spread of the virus earlier.
Reporter: What kind of immune barrier can completely end the epidemic?
Zhu Tao, chief scientific officer of CanSino Biologics: Don’t expect to be immunized once and for all.I think establishing an immune barrier requires humans and viruses to "fight" for a long time. The virus has different mutant strains. We have vaccines of different generations to fight against it. Under the action of the immune barrier, the human body is fully prepared for infection. Even if it is infected, the severity of the disease will be greatly reduced, and the virus spreads accordingly, which ultimately weakens the virus.
Reporter: Is it a prerequisite for relaxation to strengthen again?
Lizon zumab research director Hu Zhenxiang: I think it can be said that before the liberalization, we should carry out another sequential strengthening of immunity against Omickron, especially for the most risky groups after the liberalization: type is people with underlying diseases and the elderly. People like usually have a higher proportion of moderate and severe diseases after infection. If they develop severely, it may cause a shortage of medical resources. The second category of is for people in special industries, and for key groups with high exposure risks such as hospitals and customs, they also need further protection.
Source: Science and Technology Daily
Author: Zhang Jiaxing
Editor: Mao Mengnan
Review: Wang Fei
Final review: Chen Lei
